Ethiqa XR (buprenorphine) Extended-Release Injectable Suspension, 1.3mg/mL, C3 3 mL Vial

The University of Virginia awarded a contract to WA Butler Company, doing business as Covetrus North America, LLC, on June 13, 2026, for the procurement of pharmaceutical supplies. The prime contractor will deliver Ethiqa XR (buprenorphine) Extended-Release Injectable Suspension at a concentration of 1.3 milligrams per milliliter in 3-milliliter vials to the University of Virginia as the buyer. The contract encompasses a total quantity of 422 vials with a cumulative value of $422.

This contract (A207_PO-0437109-V3) represents a straightforward pharmaceutical supply procurement by a Virginia higher education institution. The unit price structure reflects a one-dollar valuation per vial, resulting in the stated cumulative contract value. The award documentation does not specify an annual value, distinct contract amount, or defined period of performance beyond the award date, nor does it identify a specific county or alternative place of performance.